AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02794285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Anifrolumab IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
Study NCT02794285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
Study NCT04437784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Trans-Abdominal Pre-Peritoneal
Description: Laparoscopic trans-abdominal pre-peritoneal repair using 2 separate meshes fixed by endoscopic tackers
Study NCT04437784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open pre-peritoneal repair
Description: Open pre-peritoneal single mesh repair with suture fixation
Study NCT04437784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Lichtenstein repair
Description: Bilateral standard Lichtenstein repair using 2 separate meshes with suture fixation
Study NCT02194270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol hydrochloride - soft pastille
Study NCT02194270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol hydrochloride - syrup - low dose
Study NCT02194270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol hydrochloride - syrup - high dose
Study NCT04014920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen group
Description: The control group will receive oxygen (first randomization), HFNO oxygen or standard oxygen (second randomization)
Study NCT04014920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV Group
Description: The experimental group will receive NIV (first randomization) alternated with HFNO or standard oxygen (second randomization)
Study NCT04618185 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI to study gut function and transit without the risk of exposure to ionising radiation.
Study NCT01508039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chitin Micro Particle
Description: The total spray volume for each application is 0.4 ml equivalent to a total single-dose for chitin of 2 mg (0.5 mg per 0.1 ml spray).~A total single-dose for LPS, of 2 mg of endotoxin from Enterobacter agglomerans (0.5 mg per 0.1 ml spray)
Study NCT03671668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: titanium bases using intra oral luting cement technique
Description: comparing between screw retained prosthesis constructed on transmucosal abutments versus titanium bases in terms of crestal bone loss and patient satisfaction
Study NCT03671668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: titanium bases using intra oral luting cement technique
Description: comparing between screw retained prosthesis constructed on transmucosal abutments versus titanium bases in terms of crestal bone loss and patient satisfaction
Study NCT02519010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine/Valsartan
Description: 1 tablet contains Amlodipine 10 mg \&valsartan 160 mg
Study NCT02519010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exforge
Description: 1 tablet contains Amlodipine 10 mg \&valsartan 160 mg
Study NCT00889538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 50 mL of 1/2 normal saline IV
Study NCT00889538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glutathione
Description: glutathione 600 mg IV
Study NCT00889538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glutathione, vit C and NAC
Description: Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL
Study NCT00542802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam tablets 250-500 mg. The drug dosage will be up-titrated from 250 mg bid in the first 2 weeks to 500 mg bid during the rest of the treatment period. The dosage can be incremented until 1500 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
Study NCT00542802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Carbamazepina tablets 200 mg. The drug dosage will be up-titrated from 100 mg die in the first 3 days to 100 mg bid during days 4 to 7, to 200 mg bid in the 2nd week, to 300 mg bid during the rest of the treatment period. The dosage can be incremented until 800 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
Study NCT03902587 — intervention group
Intervention type: DEVICE
Intervention: Samsung's E-cervix technology
Description: While patients are having their routine cervical ultrasound assessments which requires a 5 minute time period, we will use the built-in software to obtain additional E-cervix measurements to evaluate the consistency of the cervical os. This will be done within the standard 5 minute period which is typically done to observe for dynamic changes. The measurements will be obtained with the same sonogram machine, using updated software.
Study NCT02738268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment in combination with the standard skin care.
Study NCT02738268 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham laser
Study NCT01260844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: briakinumab
Description: single dose briakinumab and 2 doses of CYP substrates
Study NCT03142048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schools of Health for the Elderly
Description: The intervention School of Health for the Elderly  consists of 22 weekly group sessions of 1.5 hours each. In addition to helping participants learn about different health issues, the intervention encourages interaction among participants and works on personal skills. Furthermore, most sessions are led by professionals who are experts on the topic covered and work in the neighborhood (professionals from the health services, social services, markets or neighborhood associations), making it easier to inform participants of the neighborhood's available resources. The aim of the intervention is to decrease social isolation and loneliness and, therefore, to improve mental health, self-perceived health and wellbeing
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT, IV, or SC
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, IV, or SC
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: PO or IV
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: PO or IV
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT
Study NCT02883049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02883049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO or IV
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given PO or IV
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO
Study NCT01575834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection once every 6 months (Q6M)
Study NCT05069116 — intervention group
Intervention type: OTHER
Intervention: Training in surgery
Description: The study evaluates the training process of general surgery residents - in classic surgery, as well as laparoscopic surgery, from hospital activity to extracurricular activities.
Study NCT04232475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 minute of stair climbing and descending
Description: 3 minute of stair climbing and descending
Study NCT02543905 — intervention group
Intervention type: PROCEDURE
Intervention: Prostate MRI and Biopsy
Description: All men will be offered a MRI and prostate biopsy and they can either opt to undergo these procedures at baseline irrespective of PSA level at baseline or they can undergo PSA-only screening until clinically indicated based on an age-defined PSA threshold, at which point, they will undergo prostate MRI and biopsy once their PSA reaches the threshold.
Study NCT00454688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asimadoline
Description: Asimadoline was provided in coated tablets of three dosages (0.15 mg, 0.5 mg, and 1.0 mg). All asimadoline tablets used in this trial were synthesized from the same batch of drug substance (Batch EF418492). Asimadoline was administered orally, BID for 12 weeks
Study NCT00454688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided in coated tablets identical in appearance to asimadoline tablets.
Study NCT02169141 — intervention group
Intervention type: OTHER
Intervention: Pharmacokinetics
Description: multiple blood samples are obtained by means of an indwelling intravenous catheter for calculating PK parameters
Study NCT04562246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic assays for antibodies to SARS-CoV-2
Description: Beckman Coulter and Roche automated immunoassays
Study NCT04232475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10 minute of stair climbing and descending
Description: 10 minute of stair climbing and descending
Study NCT03980145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-EO System (Reha Technology AG: Olten, Switzerland)
Description: Electromechanically-assisted gait training addresses many of the limitations of therapist-assisted gait training and can be performed using either exoskeleton or end-effector devices. Exoskeleton devices involve programmable drives or passive elements which physically move the lower limbs, whereas, end-effector approaches involve driven footplates that have trajectories that simulate the stance and swing phases.13,14 The G-EO System (Reha Technology: Olten, Switzerland) is a novel end-effector gait training system that was developed for regaining mobility and independence in stroke survivors. This system involves minimal therapist and patient burden (e.g., quick set-up, single operate usage), there is the unique capacity for practicing walking and stair climbing movements, and the patient can receive real-time visual feedback.
Study NCT03980145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Conventional physical therapy (CPT): CPT sessions will involve a 3-5 minute warm-up, stretching, progressive strength training exercises, and gait and balance training. Additional strategies for home exercises, energy conservation, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided.
Study NCT00921557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Oral tablet taken once weekly: 70 mg if participant greater than 30 kg or 35 mg if participant less than or equal to 30 kg
Study NCT00921557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet taken once weekly
Study NCT00921557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate/vitamin D
Description: Tablet taken once or twice daily: calcium carbonate (600 mg) and vitamin D (400 IU) once daily for participants with 25-OH-vitamin D levels greater than or equal to 20 ng/mL or twice daily for those with 25-OH-vitamin D levels less than 20 ng/mL
Study NCT03055299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMEX intervention
Description: Comprehensive Exercise
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT and IV
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT and IV
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV
Study NCT02743936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal cannula
Description: Placement of nasal cannula under non-invasive positive pressure ventilation mask
Study NCT02743936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive positive pressure ventilation
Description: Non-invasive positive pressure ventilation
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IV
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV
Study NCT02743936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive positive pressure ventilation
Description: Non-invasive positive pressure ventilation
Study NCT04675671 — intervention group
Intervention type: OTHER
Intervention: Preoperative and postoperative anxiety measurement [Spielberger's State Anxiety Scale (STAI-S)] and [ Spielberg's State-Trait Anxiety Inventory (STAI-T) ]
Description: The postoperative pain is measured and evaluated by Visual Analog Scale (VAS= 0 = no pain to 10 = worst pain)
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO or IV
Study NCT02956876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard chemotherapy for colorectal cancer
Description: standard chemotherapy for colorectal cancer
Study NCT02956876 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: standard chemotherapy for colorectal cancer
Description: standard chemotherapy for colorectal cancer
Study NCT02956876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse practitioner consultation
Description: Nurse practitioner consultation will be done standard chemotherapy for colorectal cancer
Study NCT02956876 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical practitioner consultation
Description: Medical practitioner consultation will be done standard chemotherapy for colorectal cancer.
Study NCT02883049 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT02883049 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT01878253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sidus Stem-Free Total Shoulder Arthroplasty System
Study NCT02883049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02209688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESR 1150 CL
Study NCT02209688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00672347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: 1 mcg/kg
Study NCT00672347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 20 mcg/kg
Study NCT00672347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine plus clonidine and morphine
Description: bupivacaine 0,166% 1 ml/kg~clonidine 1 mcg/kg~morphine 20 mcg/kg
Study NCT00672347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Caudal anesthesia with bupivacaine 0,166% 1 ml/kg
Study NCT02959255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: dosage difference
Study NCT03305341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection
Description: * Intradermic Injection, ID~* COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection
Study NCT03637205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECLS insertion
Description: After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned. ECLS insertion should be performed preferably before revascularization
Study NCT03637205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Revascularisation and optimal medical treatment
Description: After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned.
Study NCT03637205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Revascularisation and optimal medical treatment
Description: After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned.
Study NCT03896646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo SPECT/CT HIDA scan
Study NCT03896646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hepatobiliary Iminodiacetic Acid Scan
Description: Undergo SPECT/CT HIDA scan
Study NCT03896646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT HIDA scan
Study NCT03896646 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Glass Microspheres
Description: Undergo radioembolization with yttrium Y 90 glass microspheres
Study NCT03896646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yttrium-90 Microsphere Radioembolization
Description: Undergo yttrium-90 microsphere radioembolization
Study NCT03995173 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: rTMS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P). The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
Study NCT03995173 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: rTMS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P). The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
Study NCT04947774 — intervention group
Intervention type: RADIATION
Intervention: Prophylactic Cranial Irradiation
Description: The extensive-stage SCLC patients will receive prophylactic cranial irradiation ±immunotherapy after standard first-line chemotherapy combined with immunotherapy, until disease progression or death
Study NCT04120077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EyePromise DVS, EyePromise DVS plus EyePromise EZTears
Description: Placebo Comparator: American Association of Diabetes Educators (AADE) certified Diabetes Self-Management Education (DSME) with placebo nutritional supplements
Study NCT04120077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EyePromise DVS, EyePromise DVS plus EyePromise EZTears
Description: Placebo Comparator: American Association of Diabetes Educators (AADE) certified Diabetes Self-Management Education (DSME) with placebo nutritional supplements
Study NCT00016432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: 25 mg for 5 years
Study NCT00016432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo